ABSTRACT
OBJECTIVE: To investigate the effect of low-selenium diet on the liver and kidneys of rats and explore the role of macrophage polarization into M1 and M2 phenotypes in liver and kidney injuries. METHODS: Twenty-four rats (12 female and 12 male) were randomly divided into control group and low-selenium group and fed with normal chow (dietary selenium of 0.18 mg/kg) and low-selenium diet (dietary selenium of 0.02 mg/kg) for 109 days. After the feeding, the rats were sacrificed for HE staining to observe liver and kidney pathologies, and immunohistochemistry was performed for analyzing CCR7, CD206, CD163-positive cell numbers in the liver and kidneys. RESULTS: The rats in low-selenium group showed severer fibrosis in the liver and kidney than the control group. In either male or female rats in low-selenium group, CCR7 and CD206 expressions in the liver were comparable with those in control group, but CD163 expression was lower than that in the control group (P<0.05 for both female and male rats). In the kidney, the proximal tubule showed a slightly higher while the distal tubule showed a slightly lower CCR7 expression in low selenium group than in the control group (P>0.05). In low-selenium group, a significantly lower CD163 expression in the distal tubule and a significantly higher CD206 expression in the proximal tubule were noted as compared with the control group (P<0.05 in both female and male rats). Compared with the control rats, the male rats in low-selenium group, but not the female rats, showed a significantly lower CD163 expression in the proximal tubule of the kidney (P<0.05); the female but not the male rats in low-selenium group show a higher CD206 expression in the distal tubule (P<0.05). CONCLUSION: Low-selenium diet can cause liver and kidney fibrosis in rats and may inhibit macrophage activation into the M2 phenotype.
Subject(s)
Diet , Kidney/metabolism , Liver/metabolism , Macrophage Activation , Selenium/administration & dosage , Animals , Antigens, CD/metabolism , Antigens, Differentiation, Myelomonocytic/metabolism , Female , Fibrosis , Kidney/pathology , Lectins, C-Type/metabolism , Liver/pathology , Male , Mannose Receptor , Mannose-Binding Lectins/metabolism , Rats , Receptors, CCR7/metabolism , Receptors, Cell Surface/metabolismABSTRACT
A total of 118 patients with schistosomal hepatocirrhosis were divided into an experiment group (62 cases) and a control group (56 cases), and the former received capsule Xinganbao and the latter received conventional medicine for 6 months. The reductions of serum HA, LN and PCIII were more notable in the experiment group than in the control group (P < 0.05). The clinical symptoms, physical signs, and liver function improved in both groups, and there were no significant differences between two groups. In conclusions, capsule Xinganbao has a good effect on hepatic fibrosis.